REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukaemia

This phase 2 study (N = 116) evaluated single-agent vosaroxin, a first-in-class anticancer quinolone derivative, in patients ≥60 years of age with previously untreated unfavourable prognosis acute myeloid leukaemia. Dose regimen optimization was explored in sequential cohorts (A: 72 mg/m(2) d 1, 8,...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Haematol
Main Authors: Stuart, Robert K, Cripe, Larry D, Maris, Michael B, Cooper, Maureen A, Stone, Richard M, Dakhil, Shaker R, Turturro, Francesco, Stock, Wendy, Mason, James, Shami, Paul J, Strickland, Stephen A, Costa, Luciano J, Borthakur, Gautam, Michelson, Glenn C, Fox, Judith A, Leavitt, Richard D, Ravandi, Farhad
Formato: Artigo
Idioma:Inglês
Publicado em: BlackWell Publishing Ltd 2015
Assuntos:
Haematological Malignancy
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4354261/
https://ncbi.nlm.nih.gov/pubmed/25403830
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.13214
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados